Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Page: 129

Published Date: 14 Jan 2024

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Chimeric Antigen Receptor (CAR)-T Cell Therapy industry chain, the market status of Hospital (Abecma, Breyanzi), Diagnostic Center (Abecma, Breyanzi), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Chimeric Antigen Receptor (CAR)-T Cell Therapy.

Regionally, the report analyzes the Chimeric Antigen Receptor (CAR)-T Cell Therapy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Chimeric Antigen Receptor (CAR)-T Cell Therapy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Chimeric Antigen Receptor (CAR)-T Cell Therapy industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Abecma, Breyanzi).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Chimeric Antigen Receptor (CAR)-T Cell Therapy market.

Regional Analysis: The report involves examining the Chimeric Antigen Receptor (CAR)-T Cell Therapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Chimeric Antigen Receptor (CAR)-T Cell Therapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Chimeric Antigen Receptor (CAR)-T Cell Therapy:
Company Analysis: Report covers individual Chimeric Antigen Receptor (CAR)-T Cell Therapy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Chimeric Antigen Receptor (CAR)-T Cell Therapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Diagnostic Center).

Technology Analysis: Report covers specific technologies relevant to Chimeric Antigen Receptor (CAR)-T Cell Therapy. It assesses the current state, advancements, and potential future developments in Chimeric Antigen Receptor (CAR)-T Cell Therapy areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Chimeric Antigen Receptor (CAR)-T Cell Therapy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Chimeric Antigen Receptor (CAR)-T Cell Therapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type
Abecma
Breyanzi
Kymriah
Tecartus
Yescarta
Others

Market segment by Application
Hospital
Diagnostic Center
Other

Market segment by players, this report covers
Autolus Therapeutics
CARsgen Therapeutics
Juno Therapeutics
Sorrento Therapeutics
bluebird bio
CELGENE CORPORATION
Eureka Therapeutics
Avacta Life Sciences
Calyxt
Celyad Oncology SA
Fortress Biotech
IMMUNE THERAPEUTICS
Gilead Sciences
Novartis AG
Alaunos Therapeutics
Poseida Therapeutics

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Chimeric Antigen Receptor (CAR)-T Cell Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Chimeric Antigen Receptor (CAR)-T Cell Therapy, with revenue, gross margin and global market share of Chimeric Antigen Receptor (CAR)-T Cell Therapy from 2019 to 2024.
Chapter 3, the Chimeric Antigen Receptor (CAR)-T Cell Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Chimeric Antigen Receptor (CAR)-T Cell Therapy market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Chimeric Antigen Receptor (CAR)-T Cell Therapy.
Chapter 13, to describe Chimeric Antigen Receptor (CAR)-T Cell Therapy research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Chimeric Antigen Receptor (CAR)-T Cell Therapy
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Chimeric Antigen Receptor (CAR)-T Cell Therapy by Type
        1.3.1 Overview: Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type in 2023
        1.3.3 Abecma
        1.3.4 Breyanzi
        1.3.5 Kymriah
        1.3.6 Tecartus
        1.3.7 Yescarta
        1.3.8 Others
    1.4 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market by Application
        1.4.1 Overview: Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospital
        1.4.3 Diagnostic Center
        1.4.4 Other
    1.5 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast
    1.6 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast by Region
        1.6.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region, (2019-2030)
        1.6.3 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2019-2030)
        1.6.4 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2019-2030)
        1.6.6 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2019-2030)
        1.6.7 Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 Autolus Therapeutics
        2.1.1 Autolus Therapeutics Details
        2.1.2 Autolus Therapeutics Major Business
        2.1.3 Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.1.4 Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Autolus Therapeutics Recent Developments and Future Plans
    2.2 CARsgen Therapeutics
        2.2.1 CARsgen Therapeutics Details
        2.2.2 CARsgen Therapeutics Major Business
        2.2.3 CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.2.4 CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 CARsgen Therapeutics Recent Developments and Future Plans
    2.3 Juno Therapeutics
        2.3.1 Juno Therapeutics Details
        2.3.2 Juno Therapeutics Major Business
        2.3.3 Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.3.4 Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Juno Therapeutics Recent Developments and Future Plans
    2.4 Sorrento Therapeutics
        2.4.1 Sorrento Therapeutics Details
        2.4.2 Sorrento Therapeutics Major Business
        2.4.3 Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.4.4 Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Sorrento Therapeutics Recent Developments and Future Plans
    2.5 bluebird bio
        2.5.1 bluebird bio Details
        2.5.2 bluebird bio Major Business
        2.5.3 bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.5.4 bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 bluebird bio Recent Developments and Future Plans
    2.6 CELGENE CORPORATION
        2.6.1 CELGENE CORPORATION Details
        2.6.2 CELGENE CORPORATION Major Business
        2.6.3 CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.6.4 CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 CELGENE CORPORATION Recent Developments and Future Plans
    2.7 Eureka Therapeutics
        2.7.1 Eureka Therapeutics Details
        2.7.2 Eureka Therapeutics Major Business
        2.7.3 Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.7.4 Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Eureka Therapeutics Recent Developments and Future Plans
    2.8 Avacta Life Sciences
        2.8.1 Avacta Life Sciences Details
        2.8.2 Avacta Life Sciences Major Business
        2.8.3 Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.8.4 Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Avacta Life Sciences Recent Developments and Future Plans
    2.9 Calyxt
        2.9.1 Calyxt Details
        2.9.2 Calyxt Major Business
        2.9.3 Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.9.4 Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 Calyxt Recent Developments and Future Plans
    2.10 Celyad Oncology SA
        2.10.1 Celyad Oncology SA Details
        2.10.2 Celyad Oncology SA Major Business
        2.10.3 Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.10.4 Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.10.5 Celyad Oncology SA Recent Developments and Future Plans
    2.11 Fortress Biotech
        2.11.1 Fortress Biotech Details
        2.11.2 Fortress Biotech Major Business
        2.11.3 Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.11.4 Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.11.5 Fortress Biotech Recent Developments and Future Plans
    2.12 IMMUNE THERAPEUTICS
        2.12.1 IMMUNE THERAPEUTICS Details
        2.12.2 IMMUNE THERAPEUTICS Major Business
        2.12.3 IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.12.4 IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.12.5 IMMUNE THERAPEUTICS Recent Developments and Future Plans
    2.13 Gilead Sciences
        2.13.1 Gilead Sciences Details
        2.13.2 Gilead Sciences Major Business
        2.13.3 Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.13.4 Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.13.5 Gilead Sciences Recent Developments and Future Plans
    2.14 Novartis AG
        2.14.1 Novartis AG Details
        2.14.2 Novartis AG Major Business
        2.14.3 Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.14.4 Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.14.5 Novartis AG Recent Developments and Future Plans
    2.15 Alaunos Therapeutics
        2.15.1 Alaunos Therapeutics Details
        2.15.2 Alaunos Therapeutics Major Business
        2.15.3 Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.15.4 Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.15.5 Alaunos Therapeutics Recent Developments and Future Plans
    2.16 Poseida Therapeutics
        2.16.1 Poseida Therapeutics Details
        2.16.2 Poseida Therapeutics Major Business
        2.16.3 Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
        2.16.4 Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.16.5 Poseida Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of Chimeric Antigen Receptor (CAR)-T Cell Therapy by Company Revenue
        3.2.2 Top 3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Players Market Share in 2023
        3.2.3 Top 6 Chimeric Antigen Receptor (CAR)-T Cell Therapy Players Market Share in 2023
    3.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Overall Company Footprint Analysis
        3.3.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Region Footprint
        3.3.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Type Footprint
        3.3.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value and Market Share by Type (2019-2024)
    4.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2019-2024)
    5.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast by Application (2025-2030)

6 North America
    6.1 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2019-2030)
    6.2 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2019-2030)
    6.3 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country
        6.3.1 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2019-2030)
        6.3.2 United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)
        6.3.3 Canada Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)
        6.3.4 Mexico Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2019-2030)
    7.2 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2019-2030)
    7.3 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country
        7.3.1 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2019-2030)
        7.3.2 Germany Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)
        7.3.3 France Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)
        7.3.5 Russia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)
        7.3.6 Italy Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region
        8.3.1 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2019-2030)
        8.3.2 China Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)
        8.3.3 Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)
        8.3.4 South Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)
        8.3.5 India Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)
        8.3.7 Australia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)

9 South America
    9.1 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2019-2030)
    9.2 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2019-2030)
    9.3 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country
        9.3.1 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2019-2030)
        9.3.2 Brazil Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)
        9.3.3 Argentina Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country
        10.3.1 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2019-2030)
        10.3.2 Turkey Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)
        10.3.4 UAE Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Drivers
    11.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Restraints
    11.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Industry Chain
    12.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Upstream Analysis
    12.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Midstream Analysis
    12.4 Chimeric Antigen Receptor (CAR)-T Cell Therapy Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2019-2024) & (USD Million)
    Table 4. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2025-2030) & (USD Million)
    Table 5. Autolus Therapeutics Company Information, Head Office, and Major Competitors
    Table 6. Autolus Therapeutics Major Business
    Table 7. Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 8. Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 9. Autolus Therapeutics Recent Developments and Future Plans
    Table 10. CARsgen Therapeutics Company Information, Head Office, and Major Competitors
    Table 11. CARsgen Therapeutics Major Business
    Table 12. CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 13. CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 14. CARsgen Therapeutics Recent Developments and Future Plans
    Table 15. Juno Therapeutics Company Information, Head Office, and Major Competitors
    Table 16. Juno Therapeutics Major Business
    Table 17. Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 18. Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 19. Juno Therapeutics Recent Developments and Future Plans
    Table 20. Sorrento Therapeutics Company Information, Head Office, and Major Competitors
    Table 21. Sorrento Therapeutics Major Business
    Table 22. Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 23. Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 24. Sorrento Therapeutics Recent Developments and Future Plans
    Table 25. bluebird bio Company Information, Head Office, and Major Competitors
    Table 26. bluebird bio Major Business
    Table 27. bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 28. bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 29. bluebird bio Recent Developments and Future Plans
    Table 30. CELGENE CORPORATION Company Information, Head Office, and Major Competitors
    Table 31. CELGENE CORPORATION Major Business
    Table 32. CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 33. CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 34. CELGENE CORPORATION Recent Developments and Future Plans
    Table 35. Eureka Therapeutics Company Information, Head Office, and Major Competitors
    Table 36. Eureka Therapeutics Major Business
    Table 37. Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 38. Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 39. Eureka Therapeutics Recent Developments and Future Plans
    Table 40. Avacta Life Sciences Company Information, Head Office, and Major Competitors
    Table 41. Avacta Life Sciences Major Business
    Table 42. Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 43. Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 44. Avacta Life Sciences Recent Developments and Future Plans
    Table 45. Calyxt Company Information, Head Office, and Major Competitors
    Table 46. Calyxt Major Business
    Table 47. Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 48. Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 49. Calyxt Recent Developments and Future Plans
    Table 50. Celyad Oncology SA Company Information, Head Office, and Major Competitors
    Table 51. Celyad Oncology SA Major Business
    Table 52. Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 53. Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 54. Celyad Oncology SA Recent Developments and Future Plans
    Table 55. Fortress Biotech Company Information, Head Office, and Major Competitors
    Table 56. Fortress Biotech Major Business
    Table 57. Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 58. Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 59. Fortress Biotech Recent Developments and Future Plans
    Table 60. IMMUNE THERAPEUTICS Company Information, Head Office, and Major Competitors
    Table 61. IMMUNE THERAPEUTICS Major Business
    Table 62. IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 63. IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 64. IMMUNE THERAPEUTICS Recent Developments and Future Plans
    Table 65. Gilead Sciences Company Information, Head Office, and Major Competitors
    Table 66. Gilead Sciences Major Business
    Table 67. Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 68. Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 69. Gilead Sciences Recent Developments and Future Plans
    Table 70. Novartis AG Company Information, Head Office, and Major Competitors
    Table 71. Novartis AG Major Business
    Table 72. Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 73. Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 74. Novartis AG Recent Developments and Future Plans
    Table 75. Alaunos Therapeutics Company Information, Head Office, and Major Competitors
    Table 76. Alaunos Therapeutics Major Business
    Table 77. Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 78. Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 79. Alaunos Therapeutics Recent Developments and Future Plans
    Table 80. Poseida Therapeutics Company Information, Head Office, and Major Competitors
    Table 81. Poseida Therapeutics Major Business
    Table 82. Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
    Table 83. Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 84. Poseida Therapeutics Recent Developments and Future Plans
    Table 85. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million) by Players (2019-2024)
    Table 86. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Share by Players (2019-2024)
    Table 87. Breakdown of Chimeric Antigen Receptor (CAR)-T Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 88. Market Position of Players in Chimeric Antigen Receptor (CAR)-T Cell Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
    Table 89. Head Office of Key Chimeric Antigen Receptor (CAR)-T Cell Therapy Players
    Table 90. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Type Footprint
    Table 91. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Application Footprint
    Table 92. Chimeric Antigen Receptor (CAR)-T Cell Therapy New Market Entrants and Barriers to Market Entry
    Table 93. Chimeric Antigen Receptor (CAR)-T Cell Therapy Mergers, Acquisition, Agreements, and Collaborations
    Table 94. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (USD Million) by Type (2019-2024)
    Table 95. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Share by Type (2019-2024)
    Table 96. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Forecast by Type (2025-2030)
    Table 97. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2019-2024)
    Table 98. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Forecast by Application (2025-2030)
    Table 99. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 100. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 101. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 102. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 103. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2019-2024) & (USD Million)
    Table 104. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2025-2030) & (USD Million)
    Table 105. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 106. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 107. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 108. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 109. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2019-2024) & (USD Million)
    Table 110. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2025-2030) & (USD Million)
    Table 111. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 112. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 113. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 114. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 115. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2019-2024) & (USD Million)
    Table 116. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2025-2030) & (USD Million)
    Table 117. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 118. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 119. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 120. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 121. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2019-2024) & (USD Million)
    Table 122. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2025-2030) & (USD Million)
    Table 123. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 124. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 125. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 126. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 127. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2019-2024) & (USD Million)
    Table 128. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2025-2030) & (USD Million)
    Table 129. Chimeric Antigen Receptor (CAR)-T Cell Therapy Raw Material
    Table 130. Key Suppliers of Chimeric Antigen Receptor (CAR)-T Cell Therapy Raw Materials
List of Figures
    Figure 1. Chimeric Antigen Receptor (CAR)-T Cell Therapy Picture
    Figure 2. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type in 2023
    Figure 4. Abecma
    Figure 5. Breyanzi
    Figure 6. Kymriah
    Figure 7. Tecartus
    Figure 8. Yescarta
    Figure 9. Others
    Figure 10. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 11. Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application in 2023
    Figure 12. Hospital Picture
    Figure 13. Diagnostic Center Picture
    Figure 14. Other Picture
    Figure 15. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 16. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 17. Global Market Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
    Figure 18. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Region (2019-2030)
    Figure 19. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Region in 2023
    Figure 20. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 21. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 22. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 23. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 24. Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 25. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Share by Players in 2023
    Figure 26. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
    Figure 27. Global Top 3 Players Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share in 2023
    Figure 28. Global Top 6 Players Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share in 2023
    Figure 29. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Share by Type (2019-2024)
    Figure 30. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share Forecast by Type (2025-2030)
    Figure 31. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Share by Application (2019-2024)
    Figure 32. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share Forecast by Application (2025-2030)
    Figure 33. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2019-2030)
    Figure 34. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2019-2030)
    Figure 35. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Country (2019-2030)
    Figure 36. United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 37. Canada Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 38. Mexico Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 39. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2019-2030)
    Figure 40. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2019-2030)
    Figure 41. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Country (2019-2030)
    Figure 42. Germany Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 43. France Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 44. United Kingdom Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 45. Russia Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 46. Italy Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 47. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2019-2030)
    Figure 48. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2019-2030)
    Figure 49. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Region (2019-2030)
    Figure 50. China Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 51. Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 52. South Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 53. India Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 54. Southeast Asia Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 55. Australia Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 56. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2019-2030)
    Figure 57. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2019-2030)
    Figure 58. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Country (2019-2030)
    Figure 59. Brazil Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 60. Argentina Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 61. Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2019-2030)
    Figure 62. Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2019-2030)
    Figure 63. Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Country (2019-2030)
    Figure 64. Turkey Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 65. Saudi Arabia Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 66. UAE Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 67. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Drivers
    Figure 68. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Restraints
    Figure 69. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Trends
    Figure 70. Porters Five Forces Analysis
    Figure 71. Manufacturing Cost Structure Analysis of Chimeric Antigen Receptor (CAR)-T Cell Therapy in 2023
    Figure 72. Manufacturing Process Analysis of Chimeric Antigen Receptor (CAR)-T Cell Therapy
    Figure 73. Chimeric Antigen Receptor (CAR)-T Cell Therapy Industrial Chain
    Figure 74. Methodology
    Figure 75. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Autolus Therapeutics
CARsgen Therapeutics
Juno Therapeutics
Sorrento Therapeutics
bluebird bio
CELGENE CORPORATION
Eureka Therapeutics
Avacta Life Sciences
Calyxt
Celyad Oncology SA
Fortress Biotech
IMMUNE THERAPEUTICS
Gilead Sciences
Novartis AG
Alaunos Therapeutics
Poseida Therapeutics

Related Reports

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 25 Mar 2023

date Medical Care

According to our (Global Info Research) latest study, the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Supply, Demand and Key Producers, 2023-2029

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Supply, Demand and Key Producers, 2023-2029

date 25 Mar 2023

date Medical Care

The global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Supply, Demand and Key Producers, 2024-2030

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Supply, Demand and Key Producers, 2024-2030

date 23 Feb 2024

date Medical Care

The global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

Product Tags

Chimeric Antigen Receptor (CAR) T-Cell Therapy

Chimeric Antigen Receptor (CAR)-T Cell Therapy

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>